STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS AND DRUG RESISTANCE OF BREAST TUMOR CELL LINES

10 % of genome mRNA expression is rhythmic and these 24-hrs rhythms are under control of the circadian clock. Epidemiologic studies have revealed a clear link between the disruption of circadian rhythms and cancer development in humans. Growing evidence shows that circadian disruption is associated with development of malignant tumors, including breast cancer. Aim of this study was to investigate: the expression of circadian clock genes in human mammary epithelial cell line MCF10A and breast cancer cell lines MCF-7, ZR-75-1, BT-474 and if the multidrug resistance phenotype of cancer cells is associated with changes in circadian clock genes expression. We have found that Per1 expression significantly reduced in cancer cells. No correlation was detected between the expression of circadian clock genes and cancer breast cell lines drug resistance. Interestingly, the expression of Bmal1, Per1 and Cry1 were increased in multi-drug resistant MCF-7_D cells compare with the parent cells MCF-7 cells, however, if these changes in the expression contribute to the drug-resistance or not is not clear. These results argue for further study.

circadian clock, breast cancer, multidrug resistance, cytotoxicity, anticancer drugs

1. Kondratov R.V., Antoch M.P. The clock proteins, aging and tumorigenesis. Cold Spring Harb Symp Quant Biol 2007;72:477–82.

2. Hughes M., Deharo L., Pulivarthy S.R. et al. High-resolution time course analysis of gene expression from pituitary. Cold Spring Harb Symp Quant Biol 2007;72:381–6.

3. Igarashi T., Izumi H., Uchiumi T. et al. Clock and ATF transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007;26(33):4749–60.

4. Tynes T., Hannevik M., Andersen A. et al. Incidence of breast cancers in Norwegian female radio and telegraph operators. Cancer Causes Control 1996;7(2):197–204.

5. Climent J., Perez-Losada J., Quigley D.A. et al. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 2010; 28(23):3770–8.

6. Cao Q., Gery S., Dashti A. et al. A role for the clock gene per1 in prostate cancer. Cancer Res 2009;69(19):7619–25.

7. Alhopuro P., Björklund M., Sammalkorpi H. et al. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res 2010;8(7):952–60.

8. Conlon M., Lightfoot N., Kreiger N. Rotating shift work and risk of prostate cancer. Epidemiology 2007;18(1):182–3.

9. Schernhammer E.S., Laden F., Speizer F.E. et al. Night-shift work and risk of colorectal cancer in the nurses, health study. J Natl Cancer Inst 2003;95(11):825–8.

10. Viswanathan A.N., Hankinson S.E., Schernhammer E.S. Night shift work and the risk of endometrial cancer. Cancer Res 2007;67(21):10618–22.

11. Fang L., Yang Z., Zhou J. et al. Circadian clock gene CRY2 degradation is involved in chemoresistance of colorectal cancer. Mol Cancer Ther 2015;14(6):1476–87.

12. Holliday D.L., Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011;13(4):215.

13. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25(4):402–8.

14. De Jonge H.J., Fehrmann R.S., de Bont E.S. Evidence based selection of housekeeping genes. PLoS One 2007;2(9):e898.